Want to see GB:HLN full AI Analyst Report?
HLN Stock Chart & Stats
363.50 p
9.00 p(2.48%)
At close: 4:00 PM EDT
363.50 p
9.00 p(2.48%)
Day’s Range― - ―
52-Week Range274.40 p - 416.10 p
Previous CloseN/A
Volume13.94M
Average Volume (3M)23.77M
Market Cap
£32.00B
Enterprise Value38.50K
Total Cash (Recent Filing)£1.32B
Total Debt (Recent Filing)£8.58B
Price to Earnings (P/E)19.6
Beta0.41
Next Earnings
Mar 04, 2027EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend Yield1.95%
Share Statistics
EPS (TTM)0.18
Shares Outstanding8,808,899,000
10 Day Avg. Volume25,018,353
30 Day Avg. Volume23,772,072
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£406.75Price Target Upside11.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.21
Revenue Forecast (FY)£11.40B
Bulls Say, Bears Say
Bulls Say
Consistent Free Cash Flow GenerationHaleon’s multi-year operating cash flow (~£2.1–2.3bn) and free cash flow (~£1.7–2.0bn) provide durable internal funding for reinvestment, A&P/R&D, dividends and debt reduction. Reliable cash conversion underpins strategic flexibility and resilience through demand cycles over the next 2–6 months and beyond.
Leading Oral-health Brands And Emerging-market ExecutionMulti-year strength in Oral Health (Sensodyne, Parodontax) plus robust emerging-market traction (India low-price packs, China e‑commerce growth) indicate structural revenue engines. Brand equity and scalable channel wins (digital/Douyin) support durable volume and market-share gains across regions, insulating growth vs. cyclical headwinds.
Margin Recovery And Structural Productivity ProgramsMeaningful 2025 gross‑margin expansion (≈220bps), planned $175–$200m savings and ongoing supply‑chain productivity (50–80bps) reflect structural cost base improvements. These initiatives raise sustainable operating leverage, enabling reinvestment in growth while supporting margin durability even if top-line growth remains modest.
Bears Say
Moderate Leverage Vs. Earlier YearsAlthough net debt declined in 2025, leverage remains meaningfully higher than pre-2022 levels. Elevated debt constrains capital allocation flexibility for M&A, large buybacks or aggressive investment if demand weakens, and increases sensitivity to interest-rate moves — a persistent structural constraint on long-term strategic optionality.
Weak Volume Trends And Category HeadwindsChronic low volume growth (~1% multi-year) coupled with soft U.S. performance and repeated weak cold & flu seasons point to structural demand fragility in core categories. Reliance on price/mix and A&P to offset volumes raises execution risk and limits sustainable top-line expansion without consistent recovery in volumes or category health.
Revenue Stability With Prior Margin Pressure And Asset DeclineRevenue has been roughly flat with intermittent dips, and while profitability recovered into 2025, margins were pressured earlier and total assets have declined since 2022. This combination signals constrained organic growth capability and reliance on efficiency gains to boost earnings rather than sustained top-line expansion.
HLN FAQ
What was Haleon PLC’s price range in the past 12 months?
Haleon PLC lowest share price was 274.40 p and its highest was 416.10 p in the past 12 months.
What is Haleon PLC’s market cap?
Haleon PLC’s market cap is £32.00B.
When is Haleon PLC’s upcoming earnings report date?
Haleon PLC’s upcoming earnings report date is Mar 04, 2027 which is in 209 days.
How were Haleon PLC’s earnings last quarter?
Haleon PLC released its earnings results on Jul 30, 2026. The company reported 0.043 p earnings per share for the quarter, missing the consensus estimate of 0.049 p by -0.006 p.
Is Haleon PLC overvalued?
According to Wall Street analysts Haleon PLC’s price is currently Undervalued.
Does Haleon PLC pay dividends?
Haleon PLC pays a Semiannually dividend of 4.9 p which represents an annual dividend yield of 1.95%. See more information on Haleon PLC dividends here
What is Haleon PLC’s EPS estimate?
Haleon PLC’s EPS estimate is 0.11.
How many shares outstanding does Haleon PLC have?
Haleon PLC has 8,808,899,000 shares outstanding.
What happened to Haleon PLC’s price movement after its last earnings report?
Haleon PLC reported an EPS of 0.043 p in its last earnings report, missing expectations of 0.049 p. Following the earnings report the stock price went down -2.923%.
Which hedge fund is a major shareholder of Haleon PLC?
Currently, no hedge funds are holding shares in GB:HLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£406.75 (11.90% Upside)
£406.75 (11.90% Upside)
Blogger Sentiment
Bullish
GB:HLN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth £469.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.91%
12-Months-Change
Fundamentals
Return on Equity
1.95%
Trailing 12-Months
Asset Growth
2.37%
Trailing 12-Months
Company Description
Haleon PLC
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
HLN Stock 12 Month Forecast
Average Price Target
406.75 p
▲(11.90% Upside)
Technical Analysis
Allergy Therapeutics
―
Provexis
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―









